Clinical Trial Update: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating an autologous heat shock protein gp96 vaccine for glioblastoma/glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• gp96 autologous heat shock protein vaccine (heat shock protein gp96 vaccine)

Snippet

Sponsor: Cure&Sure Biotech Co., LTD | Conditions: Glioma | Phase 1 | Status: COMPLETED